All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

  TRANSLATE

The lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lupus Hub cannot guarantee the accuracy of translated content. The lupus and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lupus Hub
Brought to you by Scientific Education Support

The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders. 

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EULAR 2025: What’s hot in lupus?

By Haimanti Mandal

Share:

Featured:

Betty DiamondBetty DiamondMurray UrowitzMurray UrowitzManuel Francisco Ugarte-GilManuel Francisco Ugarte-GilMandana NikpourMandana NikpourJames Cheng-Chung WeiJames Cheng-Chung WeiJill BuyonJill BuyonLaurent ArnaudLaurent ArnaudIoannis ParodisIoannis Parodis

Jun 9, 2025

Learning objective: After reading this article, learners will be able to cite a new clinical development in lupus.

To help navigate the exciting content being presented at European Alliance of Associations for Rheumatology Congress (EULAR 2025), we have provided recommendations for the top abstracts to look out for in lupus.

EULAR 2025: Top abstracts in Lupus

Oral abstracts

Abstract#TitlePresenterDateTime
OP0006Obinutuzumab demonstrates consistent benefit across numerous primary endpoint definitions using REGENCY study results of patients with active lupus nephritisRichard A. FurieWednesday, June 1117:20–17:30
OP0079Clinical, cellular kinetics, pharmacodynamics and biomarker data up to 12 months after YTB323 (Rapcabtagene Autoleucel), a Rapidly Manufactured CD19 CAR-T Therapy, From an Open-Label, Phase 1/2 Study in Severe Refractory SLEEric MorandWednesday, June 1117:30–17:40
OP0198Efficacy and safety of ABBV-599 (elsubrutinib and upadacitinib combination) and upadacitinib monotherapy for the treatment of systemic lupus erythematosus: Results through 104 weeks in a long-term extension StudyJoan MerrillThursday, June 1210:30–10:40 
OP0201Achievement of low disease activity and remission in patients with systemic lupus erythematosus treated with dapirolizumab pegol: 48-week results from a phase 3 trialEric MorandThursday, June 1211:00–11:10
OP0202RESET-SLE: Clinical trial evaluating rese-cel (resecabtagene autoleucel), a fully human, autologous 4-1BB anti-CD19 CAR T cell therapy in non-renal SLE and lupus nephritisSaira SheikhThursday, June 1211:10–11:20
OP0203Attainment of LLDAS and DORIS remission during anifrolumab treatment: Interim 6-month results from a multinational, observational, post-launch study of treatment effectiveness in the real worldMarta MoscaThursday, June 1211:20–11:30
LB0004Randomised, placebo-controlled phase II study of oral enpatoran, a first-in-class Toll-like receptor 7/8 inhibitor, in systemic lupus erythematosusEric MorandSaturday, June 1411:00–11:10

Posters

Abstract#TitlePresenter
POS0168Post-hoc analysis of sustained response over time in systemic lupus erythematosus patients treated with cenerimod in CARE (Phase 2 b) studyAnca Askanase
POS0170Achievement of treat to target measures with upadacitinib in patients with systemic lupus erythematosus: Phase 2 randomized SLEek clinical trial resultsEric Morand
POS0319Improved efficacy and safety outcomes in patients with systemic lupus erythematosus (SLE) treated with belimumab (BEL) versus immunosuppressants (IS), in addition to antimalarials (AM) and glucocorticoids (GC): A post hoc summary of five phase 3 trialsMariele Gatto
POS0320Treatment with anifrolumab prevents long-term organ damage compared to real-world standard of care: Findings from the LASER studyZahi Touma
POS0321Kidney-related outcomes with obinutuzumab in patients with active lupus nephritis: A pre-specified exploratory analysis of the REGENCY studyRichard A. Furie
POS0322Investigating the impact of deucravacitinib treatment on cardiovascular risk-associated biomarkers in patients with systemic lupus erythematosus: Results from the phase 2 PAISLEY studyBrittany Weber
POS0734Dapirolizumab pegol demonstrated significant improvement in systemic lupus erythematosus disease activity: Efficacy and safety results of a phase 3 trialEdward M. Vital
POS0767Achieving remission and low disease activity with belimumab versus placebo in patients with SLE excluding the glucocorticoid component from target definitions: A post hoc analysis of five phase 3 trialsIoannis Parodis
POS0781Efficacy and safety of oral deucravacitinib in patients with cutaneous manifestations of lupus erythematosus: Results from PAISLEY CLE, a global, randomized, placebo-controlled, phase 2 trialJoseph F Merola
POS0966Obinutuzumab shows promise in lupus nephritis regardless of baseline serological biomarkers: An exploratory post hoc analysis of the phase II NOBILITY studyEdward M. Vital
POS0982Impact of deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, on glucocorticoid use and flares in patients with active systemic lupus erythematosus: A post hoc analysis of the phase 2 PAISLEY trialEric Morand
POS1155Improvement of fatigue in patients with systemic lupus erythematosus treated with dapirolizumab pegol: 48-week results from a phase 3 trialIoannis Parodis
POS1224Consensus-based guidance for glucocorticoid tapering in patients with systemic lupus erythematosus: Results from a modified Delphi consensus projectEdward Vital

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EULAR 2025ObinutuzumabRaptacabtagene AutoleucelDeucravacitinibBelimumabDapirolizumab pegolRESET-SLECARESLEekLASERLupus nephritisSystemic lupus erythematosusREGENCYPAISLEYNOBILITY

Newsletter

Subscribe to get the best content delivered to your inbox